GRAIL (GRAL) CEO Joshua J. Ofman Sells $2.7M of Stock

GRAIL, Inc. Chief Executive Officer Joshua J. Ofman sold 20,000 shares of the healthcare company on October 15, 2026, for roughly $2.74 million. The transaction details emerged in a Form 4 filed with the Securities and Exchange Commission.

Inside Joshua J. Ofman's GRAIL Trade

The chief executive officer executed the sale at an average price of $136.85 per share, cutting his direct stake by about 5.5% to 342,271 shares. The transaction took place under a pre-arranged Rule 10b5-1 trading plan. On the day of the trade, the stock closed at $135.46.

Other Institutional Activity in GRAIL, Inc.

Farallon Capital Management grew its holdings by 911,000 shares, ending with 3,253,684 shares worth about $222.13 million. Baker Bros. Advisors boosted its position by 1,943,281 shares, finishing with 4,028,614 shares valued at roughly $275.03 million. Farallon Capital Management LLC grew its position by 907,804 shares, ending with 4,161,584 shares worth about $490.28 million. Baker Bros. Advisors, LP held 4,028,614 shares valued at roughly $474.61 million after a flat reporting period. Primecap Management Company added 336,309 shares to hold 2,180,106 shares worth about $256.84 million.

GRAIL, Inc. Stock Up 48.4%

The stock recently traded around $119.89 as of October 17, 2026, sitting about 11.5% below its $135.46 close on the transaction date.

Recent Earnings

GRAIL reported trailing twelve month revenue of $165.26 million and basic earnings of negative $9.69 per share, with the next earnings report scheduled for November 11, 2026.

Insider Buying and Selling at GRAIL, Inc.

Earlier insider moves included Chief Financial Officer Aaron Freidin selling 4,100 shares on September 21, 2026, for $382,679, and Joshua J. Ofman parting with 61,452 shares on the same date for $6.01 million. Later, on October 5, 2026, Officer Andrew John Partridge sold 7,873 shares at $146.39 for $1.15 million, while Aaron Freidin sold 23,619 shares at $146.39 for $3.46 million.

Analysts Set New Price Targets

Canaccord Genuity maintained a Buy rating with a $150.00 target on September 28, 2026. Guggenheim maintained a Buy rating with a $155.00 target on October 1, 2026. UBS kept a Buy rating and raised its target to $175.00 on October 2, 2026. Morgan Stanley maintained an Equal-Weight rating with a $120.00 target on October 13, 2026. TD Cowen maintained a Buy rating with a $180.00 target on the same day.

About GRAIL, Inc.

GRAIL, Inc. is a healthcare firm based in Menlo Park, California, focusing on diagnostics and research. It develops multi-cancer early detection tests, including Galleri for asymptomatic screening in adults over fifty, aimed at spotting cancer early.

Bottom Line

Market watchers will look toward the upcoming earnings report on November 11, 2026, for further financial updates. Insider transactions under Rule 10b5-1 plans provide executives a routine way to handle personal holdings.